1530.HK 3SBio Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
05:45
Jan 15
Jan 15
3SBio pipeline and Pfizer deal promising
3SBio has strong clinical data, multiple bispecific antibodies in Phase 1/2 trials and US FDA clinical approvals, plus a record Pfizer deal with $1.5 billion upfront and up to $4.8 billion in milestones; management expects busy business development and a promising 2-3 year outlook, with internationalization via Pfizer approvals.
HIGH
About 1530.HK Investor Commentary
Across the available history and selected sources, Buzzberg tracks 1530.HK (3SBio Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: Tony Ho.